Patients who may be eligible to join the trial:

  • Are at least 18 years of age.

  • Have been diagnosed with non-small cell lung cancer (NSCLC).

  • Have a tumor with a KRAS mutation (KRAS+) (the investigator can test for this if KRAS status is not known).

  • Have disease that is progressing or a recurrence, during or following treatment with at least one type of systemic therapy (chemotherapy).

  • Agree to use a highly effective contraception method during the study and for a period after the trial, if of childbearing age.

  • Must not be pregnant or breastfeeding.

Patients cannot have:

  • History of treatment with a direct and specific inhibitor of MEK or KRAS.

  • Symptomatic brain metastases requiring steroids or other local intervention.

  • Known hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or COVID-19 infection within 28 days of starting the trial.

  • An active skin disorder that has required systemic therapy within the past year.

  • History of rhabdomyolysis.

  • Concurrent ocular (eye) disorders, including glaucoma, retinal vein inclusion, corneal erosion, active or recurrent dermatitis, and other forms of serious ocular surface conditions.

  • Concurrent congestive heart failure, history of severe cardiac disease, heart attack in the past six months, arrhythmias, unstable angina, or severe obstructive pulmonary disease.

  • Inability to swallow oral medications or impaired GI absorption, or active inflammatory bowel disease.

Check to learn if you pre-qualify

If the requirements above apply, you may be eligible to participate. If you are interested in participating, please find the nearest study site to discuss the next steps. Please remember that only the trial investigator can determine whether you are eligible to participate.

View the pre-screener